Clinical Trials Logo

Sarcoma, Ewing clinical trials

View clinical trials related to Sarcoma, Ewing.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06387485 Recruiting - Osteosarcoma Clinical Trials

A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

This prospective, multi-center, randomized controlled study aims to assess the efficacy of utilizing 3D printed models in preoperative planning for the excision of tumors involving bony structures within the body. The study is expected to last approximately 12 months and involve up to 150 subjects across 3 sites. Subjects will be randomized in a 1:1 ratio into either the experimental arm, utilizing 3D printed models and imaging, or the active comparator arm, using only imaging. Primary endpoint: Operative time of surgical procedure. Secondary endpoints: Reduction of blood loss, proportion of postoperative adverse events, and negative tumor margins. Exploratory endpoints: Surgical planning ease, changes in surgical plan, and surgeon satisfaction.

NCT ID: NCT06340204 Recruiting - Ewing Sarcoma Clinical Trials

Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma

Start date: March 25, 2024
Phase: Phase 1
Study type: Interventional

The investigators explored the safety and activity of weekly irinotecan liposomes in patients with relapsed and metastatic Ewing Sarcoma.

NCT ID: NCT06243588 Recruiting - Ewing Sarcoma Clinical Trials

Identification of Prognostic Factors and Role of Radiotherapy in Patients With Ewing Sarcoma

Start date: January 25, 2024
Phase:
Study type: Observational

assess whether there is a correlation between some factors (age, sex, tumor volume, tumor site, chemotherapy-induced necrosis, radiation and biomarkers) and overall survival (OS) and relapse-free survival (RFS) in patients with Ewing sarcoma. Identification of reliable prognostic factors could help to identify high-risk patients, which may require a different treatment and follow up.

NCT ID: NCT06156410 Recruiting - Osteosarcoma Clinical Trials

Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma

Start date: October 24, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-dose ifosfamide is in the treatment of children and adults with relapsed/refractory Ewing sarcoma and osteosarcoma.

NCT ID: NCT06094101 Recruiting - Rhabdomyosarcoma Clinical Trials

Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)

PerVision
Start date: September 19, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The PerVision trial utilizes an approach of a patient-individual cancer vaccine with sarcoma-specific peptides in metastasized fusion-driven sarcoma patients determined by next generation whole exome sequencing of tumor and normal tissue as well as RNA sequencing of the tumor. This approach is applicable to all patients independent of the expression of distinct tumor associated antigens, and independent of their human leukocyte antigen-typing (HLA-typing). The results of this study can directly be translated to other tumor entities. It is an interventional, multicenter, open-label, phase I/II feasibility and early proof of concept study evaluating a personalized peptide vaccine. Primary objective is to evaluate safety and success of treatment, the latter be defined as vaccination-induced T-cell response without unacceptable toxicity.

NCT ID: NCT06068075 Recruiting - Ewing Sarcoma Clinical Trials

Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD

Start date: May 8, 2018
Phase: N/A
Study type: Interventional

This is a prospective multicenter biomarker study evaluating the prognostic impact of ctDNA detection at diagnosis in patients with Ewing sarcoma or osteosarcoma.

NCT ID: NCT06029218 Recruiting - Osteosarcoma Clinical Trials

Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy

P1V2
Start date: September 13, 2023
Phase: N/A
Study type: Interventional

Thanks to the intrinsic qualities of the proton beam, proton therapy will reduce adverse effects of irradiation. The Proteus®One is the latest generation of proton therapy equipment, enabling the Centre Antoine Lacassagne to expand its range of treatments by carrying out new proton therapy treatments. It has an innovative compact isocentric rotating head (Gantry) that allows the radiation beam to be directed at different angles around the patient. In some cases, two beams are used to treat tumours, and by convention, both beams are delivered during the same session. However, it is necessary to position the patient before each beam, which is time-consuming because 2 beams have to be positioned very precisely each day. The aim of this study is therefore to assess the toxicity of proton therapy delivered by a single daily beam compared with proton therapy delivered by two daily beams, which is the conventional technique.

NCT ID: NCT05968768 Recruiting - Ewing Sarcoma Clinical Trials

To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)

Start date: October 24, 2023
Phase: Phase 2
Study type: Interventional

Prospective, interventional, open, randomized, national, multicenter, non-commercial trial

NCT ID: NCT05918640 Recruiting - Pediatric Cancer Clinical Trials

Lurbinectedin in FET-Fused Tumors

LiFFT
Start date: July 27, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.

NCT ID: NCT05830084 Recruiting - Bone Cancer Clinical Trials

Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma

REGO-EWING
Start date: March 27, 2023
Phase: Phase 1
Study type: Interventional

New drug efficacy in ES has been disappointing in the last decades and no new drugs have been successfully introduced up to now in front line treatment. Among the tested drugs, early clinical data suggest that strategies using multi-targeted tyrosine kinase inhibitors (TKI) with anti-angiogenic activities are among the most efficient and may be beneficial in the treatment of patients with ES. Several TKI have been and are currently being tested as single-agent in patients with relapsed/refractory ES with encouraging results in phase II trials. Regorafenib has shown promising activity in Ewing sarcoma relapse setting, Nevertheless, regorafenib has never been combined with the intensive chemotherapy VDC/IE schedule and therefore this combination needs to be evaluated in order to avoid dose reduction of the current standard treatment and hence its efficacy. The current clinical trial has been therefore designed to test the feasibility of regorafenib with ES conventional chemotherapy. It consists of a phase Ib that will only recruit patients with multi-metastatic (other than lungs/pleura only) ES, that present the highest unmet medical need (2 year EFS: 33%, similar to patients with relapse/refractory ES).